Buspirone in Reducing Shortness of Breath in Patients With Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2011

Conditions
DyspneaPulmonary ComplicationsUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

buspirone hydrochloride

The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period

DRUG

Placebo

Placebo

Trial Locations (15)

13057

CCOP - Hematology-Oncology Associates of Central New York, East Syracuse

29303

CCOP - Upstate Carolina, Spartanburg

29615

CCOP - Greenville, Greenville

45429

CCOP - Dayton, Dayton

54449

CCOP - Marshfield Clinic Research Foundation, Marshfield

60201

CCOP - Evanston, Evanston

62526

CCOP - Central Illinois, Decatur

64131

CCOP - Kansas City, Kansas City

89106

CCOP - Nevada Cancer Research Foundation, Las Vegas

97225

CCOP - Columbia River Oncology Program, Portland

60612-7323

MBCCOP - University of Illinois at Chicago, Chicago

67214-3882

CCOP - Wichita, Wichita

49007-3731

CCOP - Kalamazoo, Kalamazoo

27534-9479

CCOP - Southeast Cancer Control Consortium, Goldsboro

98405-0986

CCOP - Northwest, Tacoma

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Rochester

OTHER

NCT00053846 - Buspirone in Reducing Shortness of Breath in Patients With Cancer | Biotech Hunter | Biotech Hunter